Replies to post #59172 on Progressive Care Inc (fka RXMD)

[Wangenstein]

RXMD's revenues are now up 21.6% YOY. That is a fact.

No arbitrary "control number" and no fictional "contraction analysis" changes that. That is a fact.

Oh, and May wasn't "slightly above average". Revenues were up 36% YOY. That is a fact.

RXMD's historically strongest months are still ahead of it this year. That is a fact.

Yet again, RXMD is on-track to meet or exceed its goal of $22 million in revenues for 2017, a 20% increase over 2016. That is a fact.

And, last but not least, RXMD is in the process of uplisting to OTCQB. That is a fact.

Fact is, RXMD is a great company with impressive fundamentals, and soon its share price will rise to reflect that.

[Stcgg]

RXMD is afraid of the main-stream competition getting into Rx compounding, like Walgreens and Rite-Aid. Expect a continuous decline in revenues and profits as a result. RXMD can no longer charge premium prices for this service.